SNGX — SOLIGENIX, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 812796 ·
Last close
$0.38
Market Cap
$8.27M
52W High
$1.97
52W Low
$0.28
ADV30
266,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | 0 | -2,884,838 | -2,824,965 | 6,922,640 | 6,029,430 | 3,832,735 |
| Dec 2025 | 0 | 0 | -3,474,606 | -2,896,189 | 9,235,521 | 7,936,153 | 3,943,396 |
| Sep 2025 | 0 | 0 | -2,580,483 | -2,530,947 | 11,293,917 | 10,525,335 | 3,695,941 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,777,264
Investing CF
$-2,570
Financing CF
$9,515,406
CapEx
$-2,570
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.65
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-247,876,097
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,703,806
Pretax Income TTM
$-11,460,692
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,845,476 | -11,080,380 | 9,235,521 | 3,943,396 | 5,292,125 | -10,266,553 |
| Dec 2024 | 0 | -9,464,985 | -8,266,576 | 8,966,483 | 4,848,412 | 4,118,071 | -8,403,618 |
| Dec 2023 | 0 | -7,674,156 | -6,140,730 | 9,797,326 | 7,274,904 | 2,522,422 | -8,604,109 |
| Dec 2022 | 250,000 | -14,106,035 | -13,798,339 | 14,279,717 | 16,750,543 | -2,470,826 | -12,649,021 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | $8.02M | $0.41 | — |
| LGVN | Longeveron Inc. | $8.55M | $2.81 | — |
| XCUR | EXICURE, INC. | $7.99M | $1.22 | — |
| TRAW | Traws Pharma, Inc. | $8.61M | $0.56 | — |
| IMNN | Imunon, Inc. | $7.91M | $1.41 | — |
News headlines (Yahoo Finance, 1h cache)
Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight
2026-08-20 14:31 · Yahoo
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
2026-08-12 11:25 · Yahoo
Soligenix culls topical lymphoma asset after Phase III miss
2026-08-10 11:09 · Yahoo
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
2026-08-07 11:30 · Yahoo
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
2026-06-08 11:30 · Yahoo
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
2026-05-27 11:28 · Yahoo
SNGX: Continuing to Analyze FLASH2 Data
2026-05-14 14:08 · Yahoo
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
2026-04-28 11:30 · Yahoo
SNGX Phase 3 Trial Halted on HyBryte
2026-04-28 15:06 · Yahoo
SNGX: FLASH2 Trial Recommended to Stop for Futility
2026-04-29 13:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.